ArticleTranslational lung cancer research2023

Blood tumor mutational burden and dynamic changes in circulating tumor DNA predict response to pembrolizumab treatment in advanced non-small cell lung cancer.

Simone Stensgaard et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.